Article
[Preclinical study of T cell receptor specifically reactive with KRAS G12V mutation in the treatment of malignant tumors].
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences - 18 Oct 2022
Cheng X J, Jiang D, Zhang L H, Wang J H, Li Y Z, Zhai J H, Yan B Q, Zhang L L, Xie X W, Li Z Y, Ji J F
Abstract excerpt
OBJECTIVE: KRAS gene is one of the most common mutations of proto-oncogenes in human tumors, G12V is one of the most common mutation types for KRAS. It's challenging to chemically acquire the targeted drug for this mutation. Recent studies reported that this mutation peptides can form a neoepitope for T cell recognition. Our study aims to clone the T cell receptor (TCR) which specifically recognizes the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.